772 related articles for article (PubMed ID: 26555211)
1. Infectivity-associated PrP(Sc) and disease duration-associated PrP(Sc) of mouse BSE prions.
Miyazawa K; Okada H; Masujin K; Iwamaru Y; Yokoyama T
Prion; 2015; 9(5):394-403. PubMed ID: 26555211
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of infective property of recombinant prion protein amyloids in cultured cells overexpressing cellular prion protein.
Kim DH; Lee HM; Ryou C
J Korean Med Sci; 2014 Dec; 29(12):1604-9. PubMed ID: 25469058
[TBL] [Abstract][Full Text] [Related]
3. Generation of genuine prion infectivity by serial PMCA.
Weber P; Giese A; Piening N; Mitteregger G; Thomzig A; Beekes M; Kretzschmar HA
Vet Microbiol; 2007 Aug; 123(4):346-57. PubMed ID: 17493773
[TBL] [Abstract][Full Text] [Related]
4. Sc237 hamster PrPSc and Sc237-derived mouse PrPSc generated by interspecies in vitro amplification exhibit distinct pathological and biochemical properties in tga20 transgenic mice.
Yoshioka M; Imamura M; Okada H; Shimozaki N; Murayama Y; Yokoyama T; Mohri S
Microbiol Immunol; 2011 May; 55(5):331-40. PubMed ID: 21362027
[TBL] [Abstract][Full Text] [Related]
5. Prion infectivity is encoded exclusively within the structure of proteinase K-resistant fragments of synthetically generated recombinant PrP
Wang F; Wang X; Abskharon R; Ma J
Acta Neuropathol Commun; 2018 Apr; 6(1):30. PubMed ID: 29699569
[TBL] [Abstract][Full Text] [Related]
6. Prion Infectivity Plateaus and Conversion to Symptomatic Disease Originate from Falling Precursor Levels and Increased Levels of Oligomeric PrPSc Species.
Mays CE; van der Merwe J; Kim C; Haldiman T; McKenzie D; Safar JG; Westaway D
J Virol; 2015 Dec; 89(24):12418-26. PubMed ID: 26423957
[TBL] [Abstract][Full Text] [Related]
7. Pathogenic mutations within the hydrophobic domain of the prion protein lead to the formation of protease-sensitive prion species with increased lethality.
Coleman BM; Harrison CF; Guo B; Masters CL; Barnham KJ; Lawson VA; Hill AF
J Virol; 2014 Mar; 88(5):2690-703. PubMed ID: 24352465
[TBL] [Abstract][Full Text] [Related]
8. Reconstitution of prion infectivity from solubilized protease-resistant PrP and nonprotein components of prion rods.
Shaked GM; Meiner Z; Avraham I; Taraboulos A; Gabizon R
J Biol Chem; 2001 Apr; 276(17):14324-8. PubMed ID: 11152454
[TBL] [Abstract][Full Text] [Related]
9. Quaternary structure of pathological prion protein as a determining factor of strain-specific prion replication dynamics.
Laferrière F; Tixador P; Moudjou M; Chapuis J; Sibille P; Herzog L; Reine F; Jaumain E; Laude H; Rezaei H; Béringue V
PLoS Pathog; 2013; 9(10):e1003702. PubMed ID: 24130496
[TBL] [Abstract][Full Text] [Related]
10. A Fluorescent Oligothiophene-Bis-Triazine ligand interacts with PrP fibrils and detects SDS-resistant oligomers in human prion diseases.
Imberdis T; Ayrolles-Torro A; Duarte Rodrigues A; Torrent J; Alvarez-Martinez MT; Kovacs GG; Verdier JM; Robitzer M; Perrier V
Mol Neurodegener; 2016 Jan; 11():11. PubMed ID: 26809712
[TBL] [Abstract][Full Text] [Related]
11. Treatment of SMB-S15 Cells with Resveratrol Efficiently Removes the PrP(Sc) Accumulation In Vitro and Prion Infectivity In Vivo.
Wang J; Zhang BY; Zhang J; Xiao K; Chen LN; Wang H; Sun J; Shi Q; Dong XP
Mol Neurobiol; 2016 Oct; 53(8):5367-76. PubMed ID: 26440667
[TBL] [Abstract][Full Text] [Related]
12. Biochemical Characterization of Prions.
Fiorini M; Bongianni M; Monaco S; Zanusso G
Prog Mol Biol Transl Sci; 2017; 150():389-407. PubMed ID: 28838671
[TBL] [Abstract][Full Text] [Related]
13. Prion formation, but not clearance, is supported by protein misfolding cyclic amplification.
Shikiya RA; Eckland TE; Young AJ; Bartz JC
Prion; 2014; 8(6):415-20. PubMed ID: 25482601
[TBL] [Abstract][Full Text] [Related]
14. Flow Cytometric Detection of PrP
Yamasaki T; Suzuki A; Hasebe R; Horiuchi M
J Virol; 2018 Jan; 92(1):. PubMed ID: 29046463
[TBL] [Abstract][Full Text] [Related]
15. Crossing Species Barriers Relies on Structurally Distinct Prion Assemblies and Their Complementation.
Igel-Egalon A; Laferrière F; Tixador P; Moudjou M; Herzog L; Reine F; Torres JM; Laude H; Rezaei H; Béringue V
Mol Neurobiol; 2020 Jun; 57(6):2572-2587. PubMed ID: 32239450
[TBL] [Abstract][Full Text] [Related]
16. Binding of disease-associated prion protein to plasminogen.
Fischer MB; Roeckl C; Parizek P; Schwarz HP; Aguzzi A
Nature; 2000 Nov; 408(6811):479-83. PubMed ID: 11100730
[TBL] [Abstract][Full Text] [Related]
17. Analyses of protease resistance and aggregation state of abnormal prion protein across the spectrum of human prions.
Saverioni D; Notari S; Capellari S; Poggiolini I; Giese A; Kretzschmar HA; Parchi P
J Biol Chem; 2013 Sep; 288(39):27972-85. PubMed ID: 23897825
[TBL] [Abstract][Full Text] [Related]
18. The prion's elusive reason for being.
Aguzzi A; Baumann F; Bremer J
Annu Rev Neurosci; 2008; 31():439-77. PubMed ID: 18558863
[TBL] [Abstract][Full Text] [Related]
19. Prions in skeletal muscle.
Bosque PJ; Ryou C; Telling G; Peretz D; Legname G; DeArmond SJ; Prusiner SB
Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3812-7. PubMed ID: 11904434
[TBL] [Abstract][Full Text] [Related]
20. Prion protein self-interactions: a gateway to novel therapeutic strategies?
Rigter A; Langeveld JP; van Zijderveld FG; Bossers A
Vaccine; 2010 Nov; 28(49):7810-23. PubMed ID: 20932496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
